Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...

Lenalidomide has demonstrated single-agent ... specifically neutropenia and thrombocytopenia. Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made ...

Follicular lymphoma is a diverse disease ... such as bendamustine, bortezomib, lenalidomide and anti-CD20 agents (rituximab, ofatumumab and radioimmunotherapy). Finally, hematopoietic stem ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

"Having additional treatment options for people with follicular lymphoma, where multiple prior ... looking at the combination of the drug with lenalidomide in second-line FL, while SUNMO is ...

Opdivo plus AVD showed superior PFS and EFS compared to Adcetris plus AVD in patients with advanced Hodgkin lymphoma. The Opdivo regimen had a better side effect profile, with fewer severe side ...

▎药明康德内容团队编辑Incyte日前在今年的美国血液学会（ASH）年会的摘要中，公布其CD19靶向单抗Monjuvi（tafasitamab）在关键性3期临床试验inMIND中获得积极结果。分析显示，tafasitamab联合来那度胺（len）和C ...

Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.

Non-Hodgkin lymphoma is a cancer that affects lymphocytes, a type of white blood cells in the lymphatic system. They are generally classified according to the cancer's growth rate as high grade ...